Financial Performance - The company's operating revenue for 2021 was RMB 2,303,032,719, representing a 26.61% increase compared to RMB 1,819,006,691 in 2020[19]. - Net profit attributable to shareholders reached RMB 69,622,537, a significant increase of 120.41% from a loss of RMB 341,202,593 in 2020[21]. - The net profit after deducting non-recurring gains and losses was RMB 38,620,696, up 111.21% from a loss of RMB 344,510,890 in the previous year[22]. - Cash flow from operating activities increased by 85.94%, totaling RMB 184,263,469 compared to RMB 99,097,235 in 2020[19]. - Basic and diluted earnings per share were both RMB 0.13, a 120.31% increase from a loss of RMB 0.64 in 2020[20]. - The weighted average return on equity rose to 3.01%, an increase of 20.88 percentage points from -17.87% in 2020[20]. - The total assets at the end of 2021 were RMB 3,148,970,121, a 1.65% increase from RMB 3,097,971,351 at the end of 2020[19]. - The net assets attributable to shareholders increased by 2.94% to RMB 2,344,283,895 from RMB 2,277,367,601 in 2020[19]. - The company disposed of an investment subsidiary, generating an investment income of over RMB 28,100,000, contributing to the profit growth[22]. Dividend Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares, totaling 53,407,162.8 RMB based on a total share capital of 534,071,628 shares as of December 31, 2021[4]. - The cash dividend policy is in compliance with the company's articles of association and has clear standards and ratios for distribution[200]. Risk Management - The company emphasizes that forward-looking statements regarding future plans and development strategies do not constitute a substantive commitment to investors, highlighting the importance of investment risk awareness[5]. - The company has detailed potential risks in the section discussing future development in the annual report[6]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[6]. - There are no violations of decision-making procedures regarding external guarantees[6]. - The company is closely monitoring industry policy changes and regulatory risks, establishing a dynamic warning mechanism to adapt to new regulations and maintain profitability[155]. Research and Development - The company continues to innovate in drug research and development, achieving multiple technological advancements and applying for national patents[36]. - Research and development expenses rose to CNY 50.95 million, reflecting a 19.06% increase from the previous year[83]. - The company holds a total of 133 patents, including 84 invention patents, enhancing its market competitiveness[80]. - The company is increasing investment in R&D for traditional Chinese medicine products, focusing on optimizing production processes and enhancing quality control standards[112]. - The company is conducting evidence-based medical research on sodium cantharidate products to explore further indications and derivative development[113]. Market Position and Strategy - The company is focusing on brand building as a systematic project to enhance its industry position and brand image[44]. - The company has a market share leading position in its core product, the sodium cantharidate series, which is a unique product in the country[68]. - The company collaborates with well-known hospitals for clinical research and technology transfer, enhancing its competitive edge in the industry[73]. - The company is actively exploring the dermatology and chronic disease segments, emphasizing the development of unique and key products to address chronic diseases and skin conditions[146]. - The company is positioned to leverage policy advantages and market demand in the pharmaceutical sector, particularly in response to the COVID-19 pandemic and related healthcare needs[110]. Corporate Governance - The company has established a robust corporate governance structure to ensure independent operations and protect shareholder rights[169]. - The board of directors consists of 9 members, including 3 independent directors, meeting the requirement of one-third independence[170]. - The company has established performance evaluation standards and procedures for senior management[171]. - The company has implemented a management system for information disclosure to ensure timely and accurate information sharing with shareholders[171]. - The company respects the rights of stakeholders, including creditors and employees, to promote sustainable development[171]. Operational Efficiency - The company is committed to cost control and efficiency improvement through lean management initiatives, aiming to reduce production costs and enhance operational efficiency[150]. - The company is enhancing its internal control systems to mitigate operational risks and improve efficiency, focusing on compliance and risk prevention measures[151]. - The company has implemented online operations and remote video meetings to ensure stable product quality and market supply during the pandemic[157]. - The company is enhancing procurement management and establishing strategic inventory reserves to mitigate raw material cost pressures[159]. Employee Management - The total number of employees in the parent company and major subsidiaries is 1,371, with 7 in the parent company and 1,364 in subsidiaries[194]. - The workforce includes 514 production personnel, 115 sales personnel, 221 technical personnel, 47 financial personnel, and 474 administrative personnel[194]. - The company emphasizes performance-based salary structures, linking employee compensation to company and individual performance[195]. - Future adjustments to the salary system will consider operational results and local market conditions to enhance employee benefits[196]. - The company has implemented targeted training programs to improve employee skills and overall management levels[197].

2021 年第三季度报告 证券代码：600613 证券简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2021 年第三季度报告 2021 年 10 月 1 / 13 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告期 末比上年同期 | | | --- | --- | --- | --- | --- | --- | | | | 期增减变 | | 增减变动幅度 | | | | | 动幅度(%) | | (%) | | | 营业收入 | 547,399,983.42 ...

Financial Performance - The company's operating revenue for the first half of 2021 reached ¥1,155,688,396.85, representing a 37.69% increase compared to ¥839,327,318.01 in the same period last year[20]. - The net profit attributable to shareholders of the listed company was ¥44,371,523.59, up 55.52% from ¥28,530,267.49 in the previous year[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥45,681,482.77, an increase of 48.85% compared to ¥30,688,798.42 in the same period last year[20]. - The net cash flow from operating activities was ¥83,918,218.30, showing a significant increase of 113.64% from ¥39,280,109.64 in the previous year[20]. - Basic earnings per share increased by 33.33% to CNY 0.08 compared to the same period last year[21]. - Net profit attributable to shareholders increased by 55.52%, amounting to CNY 1,584.13 million, primarily due to growth in pharmaceutical manufacturing sales[22]. - Operating cash flow increased by 113.64%, reaching CNY 4,463.81 million, driven by increased sales revenue[22]. - The total comprehensive income for the first half of 2021 was CNY 37,793,885.71, up from CNY 30,553,561.52 in the first half of 2020, representing a growth of 23.3%[117]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,114,003,027.90, a slight increase of 0.52% from ¥3,097,971,351.94 at the end of the previous year[20]. - The total liabilities decreased to ¥46,858,516.86 from ¥49,467,819.40, indicating a reduction of approximately 5.4%[114]. - The company's total assets as of June 30, 2021, were ¥2,013,511,931.94, a slight decrease from ¥2,026,364,001.01 at the end of 2020[114]. - The total liabilities at the end of the reporting period were CNY 1,046,961,549.50, which is an increase from CNY 1,018,431,282 in the previous year, representing a growth of approximately 2.8%[145]. - The company's long-term equity investment totaled CNY 2.6793 million, primarily in Sichuan Magic Kangzheng Pharmaceutical Co., Ltd.[56]. Revenue Sources - Revenue from pharmaceutical manufacturing increased by CNY 239.36 million, a growth of 47.08%, with cold and cough products seeing a significant increase of 277.14%[21]. - The proportion of revenue from pharmaceutical manufacturing accounted for 65.56% of total revenue during the reporting period[27]. - The pharmaceutical manufacturing industry achieved a revenue of CNY 1,404.69 billion in the first half of 2021, representing a year-on-year increase of 28%[32]. Research and Development - The company focuses on R&D in eight major therapeutic areas, including anti-tumor and cardiovascular drugs, to enhance its industry competitiveness[28]. - Research and development expenses rose by 21.05% to ¥17,246,284.34, reflecting the company's commitment to enhancing product competitiveness[52]. - The company emphasizes the development of patent technology to protect its core product intellectual property[42]. Market and Competitive Position - The company has established a comprehensive marketing system covering most regions of the country, enhancing its competitive advantage[27]. - The company has optimized its marketing layout and strengthened control over commercial channels to improve market coverage and product penetration[44]. - The company is positioned to benefit from the growing demand for traditional Chinese medicine, supported by favorable government policies[40]. Risks and Challenges - The company has detailed various risks faced in its production and operation processes in the report[8]. - The ongoing COVID-19 pandemic has caused a decline in product sales due to lockdowns and reduced hospital visits, with uncertainty regarding the duration and extent of the impact[67]. - Rising raw material prices and the inability to pass costs onto consumers pose a risk to the company's profit margins, necessitating strategic procurement and inventory management[73]. - The ongoing national medical reform and dynamic adjustment of drug prices may impact the company's bidding success and pricing strategies[71]. Corporate Governance and Compliance - The company has not proposed any profit distribution plan or capital reserve transfer to increase share capital for this reporting period[6]. - The company has not faced any major litigation or arbitration matters during the reporting period[88]. - The actual controller and major shareholders of the company have maintained a good integrity record without any administrative or criminal penalties related to the securities market[88]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 46,656[98]. - The largest shareholder, Guizhou Shenqi Investment Co., Ltd., holds 131,301,620 shares, representing 24.59% of the total shares[100]. - The second-largest shareholder, Guizhou Maijisi Investment Management Co., Ltd., holds 88,001,946 shares, accounting for 16.48% of the total shares[100]. Financial Reporting and Standards - The company's financial statements were approved by the board of directors on April 30, 2021, ensuring compliance with regulatory standards[156]. - The financial statements are prepared in accordance with the Chinese Accounting Standards, reflecting the company's financial position, operating results, and cash flows accurately[160]. - The company recognizes cash equivalents as short-term, highly liquid investments that are easily convertible to known amounts of cash[173].

Financial Performance - Total revenue for Q1 2021 reached RMB 552.79 million, a 61.17% increase compared to RMB 342.99 million in the same period last year[10] - Net profit attributable to shareholders was RMB 21.80 million, representing a 151.21% increase from RMB 8.68 million year-on-year[5] - Operating cash flow net amount was RMB 53.02 million, a significant increase of 255.71% compared to RMB 14.90 million in the previous year[10] - The weighted average return on net assets increased to 0.93%, up 181.82% from 0.33% in the previous year[5] Investment and Expenses - Research and development expenses surged by 391.16% to RMB 9.55 million, reflecting the company's increased investment in R&D[10] - The company’s sales expenses increased by 105.29% to RMB 247.87 million, driven by higher sales revenue[10] Assets and Liabilities - Total assets at the end of the reporting period were RMB 3.16 billion, up 2.14% from RMB 3.10 billion at the end of the previous year[5] - The company reported a significant increase in accounts receivable, which rose by 121.60% to RMB 53.94 million due to increased revenue and bank acceptance bill collections[9] Shareholder Information - The number of shareholders at the end of the reporting period was 42,952, indicating a stable shareholder base[6] - The company has no overdue commitments or significant changes in expected cumulative net profit for the year[10]

Financial Performance - The company's operating revenue for 2020 was approximately ¥1.82 billion, a decrease of 5.63% compared to ¥1.93 billion in 2019[22]. - The net profit attributable to shareholders for 2020 was a loss of approximately ¥341.20 million, a decline of 506.32% from a profit of ¥83.97 million in 2019[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately -¥344.51 million, down 519.06% from ¥82.21 million in 2019[22]. - The net cash flow from operating activities for 2020 was approximately ¥99.10 million, a decrease of 22.75% from ¥128.28 million in 2019[22]. - The total assets at the end of 2020 were approximately ¥3.10 billion, a decrease of 12.88% from ¥3.56 billion at the end of 2019[22]. - The net assets attributable to shareholders at the end of 2020 were approximately ¥2.28 billion, down 12.98% from ¥2.62 billion at the end of 2019[22]. - The company's basic and diluted earnings per share for 2020 were both -0.64 yuan, a decrease of 500.00% compared to 0.16 yuan in 2019[23]. - The total profit for 2020 was -340.28 million yuan, representing a year-on-year decline of 414%[77]. - The net profit attributable to shareholders was -341.20 million yuan, down 506.32% year-on-year, with a diluted earnings per share of -0.64 yuan, a decrease of 500%[77]. Operational Challenges - The company will not distribute cash dividends or bonus shares for the year 2020 due to operational losses and significant investment needs for the Sha Wen project[6]. - The net profit attributable to shareholders decreased by 506.32% year-on-year, primarily due to a provision for bad debts of 175.07 million yuan and goodwill impairment of 162.07 million yuan[24]. - Operating revenue for the reporting period decreased by 5.63% year-on-year, mainly due to a decline in pharmaceutical sales caused by the COVID-19 pandemic[24]. - The net cash flow from operating activities decreased by 22.75% year-on-year, primarily due to a reduction in cash received from sales[24]. - The company reported a net profit of -175.49 million yuan in Q3 2020 and -194.24 million yuan in Q4 2020, indicating ongoing financial challenges[27]. Research and Development - Research and development expenses increased by 114.39% year-on-year, indicating a significant investment in innovation[24]. - The company has established a comprehensive R&D system focusing on eight major therapeutic areas, enhancing its competitive edge in the pharmaceutical industry[35]. - The company is advancing the Shawan production and R&D industrial park, with 11 production lines ready and awaiting GMP compliance checks[88]. - The company is actively engaged in the research and development of ethnic medicinal materials, enhancing quality standards and product reserves[86]. - The company has ongoing research projects for sodium cantharidate vitamin B6 injection, targeting liver cancer and other conditions, with plans for clinical application[134]. Market Dynamics - The pharmaceutical manufacturing revenue accounted for 65.56% of total operating revenue, while pharmaceutical commercial revenue accounted for 34.44%[34]. - The pharmaceutical manufacturing segment saw a revenue decrease of CNY 25,415,080, a decline of 17.57%[97]. - The pharmaceutical commercial segment, however, increased revenue by CNY 14,556,430, an increase of 30.27%[97]. - The overall revenue for the pharmaceutical commercial sector was ¥5,416.91 billion, reflecting a growth of 3.40%, with net profit increasing by 12.79% to ¥143.24 billion, supported by the performance of retail chain pharmacies[60]. - The COVID-19 pandemic significantly impacted the pharmaceutical industry, leading to a decline in revenue and profits in Q1 2020, but a recovery was observed by June with profit growth turning positive[42]. Regulatory and Compliance - The company has received a standard unqualified audit report from its accounting firm, indicating the financial statements are accurate and complete[5]. - The company has passed all regulatory inspections with no instances of non-compliance, ensuring high product quality and safety[73]. - The company adheres to a centralized procurement strategy, ensuring compliance and efficiency in sourcing raw materials and packaging, with a focus on quality and safety in production processes[36]. - The company is adapting to regulatory changes in the pharmaceutical industry, including the implementation of the MAH system to promote innovation and resource optimization[68]. - The national medical insurance catalog adjustments in 2020 included 162 drugs, with 119 successfully negotiated, affecting the competitiveness of the company's prescription products[168]. Environmental and Social Responsibility - The company emphasizes environmental protection and has increased investment in pollution control measures to align with national sustainable development goals[196]. - The Longli branch upgraded its wastewater treatment system in early 2018, which has been operating well since September 2018, ensuring compliance with environmental regulations[198]. - The company actively responded to the COVID-19 pandemic by organizing the production of necessary medicines and donated medical supplies to frontline workers in Wuhan and impoverished areas in Guizhou Province[195]. - The Longli branch's environmental monitoring data is shared on the national pollution source monitoring information management platform to ensure timely and accurate reporting[199]. - The company has been recognized for its contributions to pandemic prevention and poverty alleviation, receiving honors from the All-China Federation of Industry and Commerce[195]. Strategic Initiatives - The company plans to focus on expanding its pharmaceutical commerce segment to offset declines in manufacturing revenue[100]. - The company is exploring new product development and market expansion strategies to enhance future growth prospects[100]. - The company aims to enhance brand value and market influence through continuous innovation and quality improvement[152]. - The company will pursue both internal innovation and external acquisitions to expand its product offerings and scale[153]. - The company recognizes the growing potential of the health industry post-pandemic and plans to leverage e-commerce channels and community platforms to drive product growth[162].

2021 年第一季度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2021 年第一季度报告 2021 年 4 月 1 / 21 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 7 | 2021 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | 本报告期末 | 上年度末 | 本报告期末比上年度 | | --- | --- | --- | --- | | | | | 末增减(%) | | 总资产 | 3,164,307,522.46 | 3,097,971,351.94 | 2.14 | | 归属于上市公司 | 2,293,246,742.62 | 2,277,367,601.10 | 0.70 | | 股东的净资产 | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | 经营活动产生的 | 53,017,693.53 | 14,904,611.03 | 255.71 | | ...

2020 年第三季度报告 公司代码： 600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2020 年第三季度报告正文 2020 年 10 月 1 / 7 2020 年第三季度报告 一、 重要提示 二、 公司主要财务数据和股东变化 2.1 主要财务数据 2 / 7 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 3,329,466,226.78 3,556,129,011.94 -6.37 归属于上市公司 股东的净资产 2,471,920,637.76 2,616,935,698.11 -5.54 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减(%) 经营活动产生的 现金流量净额 46,442,467.26 105,543,021.65 -56.00 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减 （%） 营业收入 1,329,402,092.59 1,420,774,426.01 -6.43 归属于上市公司 股东的净利润 -146,963,628.0 ...

2020 年第三季度报告 公司代码：600613 公司简称：神奇制药 900904 神奇 B 股 上海神奇制药投资管理股份有限公司 2020 年第三季度报告 2020 年 10 月 1 / 24 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2020 年第三季度报告 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张芝庭、主管会计工作负责人李发淼及会计机构负责人（会计主管人员）王霞娟 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 24 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 3,329,466,226.78 3,556,129,011.94 -6.37 归属于上市公司 股东的净资产 2,471,920,637.76 2,616,935,698.11 -5.54 年初至报告期末 （1-9 月） 上年 ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥839,327,318.01, a decrease of 7.87% compared to ¥911,009,600.51 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥28,530,267.49, down 50.08% from ¥57,149,229.91 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥30,688,798.42, a decrease of 45.43% compared to ¥56,235,803.84 in the same period last year[19]. - The net cash flow from operating activities was ¥39,280,109.64, down 41.53% from ¥67,183,416.47 in the previous year[19]. - The company's basic and diluted earnings per share decreased by 45.45% to CNY 0.06 compared to the same period last year[20]. - The net profit attributable to shareholders decreased by 50.08%, amounting to a reduction of CNY 28.62 million, primarily due to decreased sales in the pharmaceutical manufacturing sector[21]. - The operating cash flow net amount decreased by 41.53%, resulting in a decline of CNY 27.90 million, attributed to reduced sales revenue in the pharmaceutical manufacturing sector[21]. - The weighted average return on net assets decreased by 1.15 percentage points to 1.08% compared to the same period last year, mainly due to the decline in sales revenue[21]. - The company experienced a 7.87% decrease in total operating revenue, amounting to a reduction of CNY 71.68 million, with a significant impact from COVID-19 on sales of cold and cough medications[20]. - The sales of cough medications dropped by 67.79%, resulting in a decrease of CNY 54.59 million due to restrictions on sales in hospitals[20]. Assets and Liabilities - The net assets attributable to shareholders at the end of the reporting period were ¥2,644,724,228.63, an increase of 1.06% from ¥2,616,935,698.11 at the end of the previous year[19]. - Total assets at the end of the reporting period were ¥3,493,802,463.57, a decrease of 1.75% from ¥3,556,129,011.94 at the end of the previous year[19]. - The company's cash and cash equivalents increased to ¥512,790,239.83, representing 14.68% of total assets, up 42.35% from ¥360,220,096.71 last year[52]. - Accounts receivable decreased significantly by 77.07% to ¥23,030,023.37, down from ¥100,416,203.88, which accounted for 0.66% of total assets[52]. - The company reported a substantial increase in construction in progress, rising by 57.01% to ¥490,630,263.86, compared to ¥312,477,377.68 in the previous year, representing 14.04% of total assets[53]. - Short-term borrowings decreased by 67.63% to ¥32,719,000 from ¥101,080,000, which accounted for 0.94% of total liabilities[54]. - The company’s long-term borrowings increased significantly by 1,973.33% to ¥311,000,000 from ¥15,000,000, representing 8.90% of total liabilities[54]. - Total liabilities decreased from CNY 894,598,007.27 to CNY 801,717,897.38, a reduction of about 10.4%[108]. - Current liabilities decreased from CNY 583,452,993.03 to CNY 446,507,406.87, a decrease of approximately 23.5%[108]. Research and Development - The company plans to enhance its R&D capabilities by focusing on eight major therapeutic areas, including anti-tumor and cardiovascular drugs[28]. - Research and development expenses increased by 17.52% to ¥14.25 million, attributed to the separate accounting of R&D expenses from certain subsidiaries during the reporting period[51]. - The company is continuing its research on the sodium cantharidate series products and expanding the potential of ethnic medicinal materials, with ongoing projects to upgrade quality standards for various traditional Chinese medicines[44]. - The company aims to develop a new profit growth point by selecting ethnic medicinal varieties for secondary research and development, targeting products with potential sales exceeding ¥100 million[45]. Market and Sales Strategy - The company has established a comprehensive sales network covering most regions of the country, with a focus on a specialized sales team and a unique marketing management model[29]. - The company has established a product-based marketing team to ensure sustainable market development, focusing on professional terminal promotions and exploring e-commerce sales platforms as a supplement[30]. - Prescription drug sales are primarily conducted through a model of "agent cooperation + professional academic promotion + self-built marketing team," covering most provinces in China[30]. - The pharmaceutical manufacturing revenue accounted for 60.58% of total operating revenue, while the pharmaceutical commercial revenue accounted for 39.42%[27]. Risk Management - The report includes a risk statement regarding forward-looking statements, indicating that future plans do not constitute a substantive commitment to investors[5]. - The company faces risks from potential public health emergencies that could lead to a significant decline in product sales, as seen during the COVID-19 pandemic[62]. - The company is actively monitoring industry policy changes, such as the new Drug Administration Law and price control measures, which could impact profitability[64]. - The company has established a dynamic warning mechanism to adapt to regulatory changes and improve its operational strategies accordingly[64]. - The company faces risks of profit margin squeeze due to upstream raw material price increases, which cannot be passed down to downstream drug prices[72]. Corporate Governance - There were no plans for profit distribution or capital reserve transfer to increase share capital during the reporting period[4]. - The company has not faced any non-operating fund occupation by controlling shareholders or related parties[6]. - The report has not been audited, but the management has guaranteed its accuracy and completeness[7]. - The company continues to employ Lixin Accounting Firm for the 2020 audit, as approved by the 2019 annual general meeting[80]. - The actual controllers and major shareholders have maintained a good integrity record without administrative or criminal penalties during the reporting period[81]. Social Responsibility - The company donated approximately ¥4.5 million worth of medical supplies to support the fight against COVID-19 in Hubei province and an additional ¥1.01 million for poverty alleviation efforts in Guizhou province[43]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 51,326[93]. - The top shareholder, Guizhou Shenqi Investment Co., Ltd., holds 131,301,620 shares, accounting for 24.59% of total shares[96]. - Guizhou Maijisi Investment Management Co., Ltd. holds 88,001,946 shares, representing 16.48% of total shares[96]. - Zhang Zhijun holds 40,007,750 shares, which is 7.49% of total shares[96]. Accounting Policies - The financial statements are prepared in accordance with the Chinese Accounting Standards and reflect the company's financial position, operating results, and cash flows accurately[153]. - The company uses Renminbi as its accounting currency[156]. - The company applies the first-in, first-out (FIFO) method for inventory valuation upon issuance[186]. - The company recognizes long-term equity investments using the cost method for subsidiaries and the equity method for joint ventures and associates[194].

Financial Performance - Operating revenue for the first quarter was CNY 342,993,999, representing a decrease of 19.56% year-on-year[7]. - Net profit attributable to shareholders was CNY 8,677,484, down 63.44% compared to the same period last year[7]. - Basic earnings per share decreased by 50.00% to CNY 0.02 compared to CNY 0.04 in the previous year[7]. - The weighted average return on equity dropped to 0.33%, down 0.60 percentage points from the previous year[7]. - The net profit for Q1 2020 was CNY 11,008,981.12, a decrease of 47.97% compared to CNY 21,158,809.18 in the same period last year[12]. - Total revenue for Q1 2020 was ¥342,993,999.78, a decrease of 19.5% compared to ¥426,384,693.33 in Q1 2019[25]. - Net profit for Q1 2020 was ¥11,008,981.12, a decline of 48.0% from ¥21,158,809.18 in Q1 2019[26]. - The company reported a total comprehensive income of ¥3,607,340.58 for Q1 2020, significantly lower than ¥33,243,253.35 in Q1 2019[26]. - The total comprehensive income for Q1 2020 was a loss of CNY 8,880,376.17, compared to a gain of CNY 10,406,512.58 in Q1 2019[29]. Cash Flow - Cash flow from operating activities showed a net inflow of CNY 14,904,611, a significant decline of 71.69% year-on-year[7]. - The company's cash flow from operating activities decreased by 71.69% to CNY 14,904,611.03, down from CNY 52,642,944.73 in the previous year[12]. - The net cash flow from operating activities in Q1 2020 was CNY 14,904,611.03, down 71.7% from CNY 52,642,944.73 in Q1 2019[32]. - The company reported a significant decrease in cash inflows from operating activities, totaling CNY 368,423,652.45 in Q1 2020, compared to CNY 461,475,742.51 in Q1 2019, a decline of approximately 20.1%[32]. - The net cash flow from operating activities for Q1 2020 was -687,868.75, a decrease of 51% compared to -1,405,475.44 in Q1 2019[36]. - The cash and cash equivalents at the end of Q1 2020 were CNY 552,355,855.66, a decrease from CNY 596,052,428.52 at the beginning of the quarter[33]. Assets and Liabilities - Total assets at the end of the reporting period reached CNY 3,604,498,926, an increase of 1.36% compared to the end of the previous year[7]. - The total assets as of March 31, 2020, were CNY 3,604,498,925.99, compared to CNY 3,556,129,011.94 at the end of 2019[18]. - The total liabilities as of March 31, 2020, were CNY 939,360,580.74, an increase from CNY 894,598,007.27 year-on-year[19]. - Total liabilities for Q1 2020 were 894,598,007.27, remaining consistent with the previous year[41]. - Total assets amounted to approximately $2.03 billion, with current assets at about $219.79 million and non-current assets at approximately $1.81 billion[44]. - Total liabilities were reported at approximately $49.07 million, with current liabilities totaling around $33.51 million and non-current liabilities at about $15.55 million[45]. - The company’s total liabilities and shareholders' equity matched the total assets, confirming a balanced financial position at $2.03 billion[45]. Shareholder Information - The total number of shareholders at the end of the reporting period was 49,531[9]. - The largest shareholder, Guizhou Magic Investment Co., Ltd., held 131,301,620 shares, accounting for 24.59% of the total shares[9]. - The total equity attributable to shareholders as of Q1 2020 was 2,616,230,980.01, consistent with the previous year[41]. Research and Development - Research and development expenses increased by 43.35% to CNY 1,943,360.73 from CNY 1,355,690.42 year-on-year[12]. - Research and development expenses for Q1 2020 were ¥1,943,360.73, an increase from ¥1,355,690.42 in Q1 2019[25]. - The company incurred research and development expenses, although specific figures were not disclosed in the provided data[28]. Government Support and Non-Operating Loss - The company received government subsidies totaling CNY 976,277, which included various forms of support related to the COVID-19 pandemic[9]. - The company reported a significant non-operating loss of CNY 2,587,422 due to donations made in response to the pandemic[9]. - The company anticipates potential losses or significant changes in net profit compared to the previous year due to ongoing challenges[13].